Cencora Announces Q3 Fiscal 2024 Earnings Release Date and Conference Call Cencora, Inc. (NYSE: COR) has announced plans to release its Third Quarter Fiscal 2024 results on Wednesday, July 31, 2024, before the New York Stock Exchange opens for trading.…
MDPI is delighted to announce the opening of nominations for the 2024 Tu Youyou Award, a prestigious recognition established in honor of Professor Tu Youyou, Nobel Laureate, whose discovery has significantly impacted the global fight against malaria. The Tu Youyou…
During its annual event “BIG UP,” French Tech Saint-Etienne Lyon awarded the BIG Start-up of the Year trophy to a start-up that exemplifies the region’s innovation and richness. French Tech Saint-Etienne Lyon, a non-profit association established in 2015, promotes the…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that its Phase II/III SKYSCRAPER-06 study did not achieve its primary endpoints in evaluating tiragolumab in combination with Tecentriq® (atezolizumab) and chemotherapy compared to pembrolizumab and…
MSD, known as Merck outside the United States and Canada, will host its second-quarter 2024 sales and earnings conference call for institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 30. During the call, company executives will provide…
UCB, a global biopharmaceutical company, has unveiled new research findings supporting its recently launched treatments in the generalized myasthenia gravis (gMG) portfolio. These findings will be presented at the 10th Congress of the European Academy of Neurology (EAN) from June…
Roche’s PiaSky Receives Positive CHMP Opinion for PNH Treatment in EU Today, Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended PiaSky® (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). PiaSky,…
Roche announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for extending the marketing authorization of Vabysmo® (faricimab) to include the treatment of visual impairment due to macular edema…
AbbVie announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for inflammatory diseases. Celsius’ lead investigational asset, CEL383, is a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study…
As the world’s largest pure-play consumer health company by revenue, Kenvue has released its first-ever Healthy Lives Mission Report, highlighting the company’s efforts to enhance the well-being of both people and the planet in 2023. “We recognize that human health…
Bayer AG and Charité – Universitätsmedizin Berlin Unveil Plans for Berlin Center Advancing Gene and Cell Therapies Today, Bayer AG and Charité – Universitätsmedizin Berlin announced their joint initiative to establish the Berlin Center for Gene and Cell Therapies, bolstered…
Takeda today announced positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized…
